Clinical impact of adjuvant chemotherapy in glioblastoma multiforme a meta-analysis

CNS Drugs

Volumn 21, Issue 9, 2007, Pages 775-787

  Spiegel, Brennan M R ^a,b,c   Esrailian, Eric ^b,c   Laine, Loren ^d   Chamberlain, Marc C ^e  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; DACARBAZINE; LEVAMISOLE; LOMUSTINE; MELATONIN; MITOLACTOL; NALTREXONE; NIMUSTINE; NITROSOUREA DERIVATIVE; PLACEBO; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; GLIOBLASTOMA; HUMANS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 34548076589     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721090-00006     Document Type: Article

References (40)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108
2. Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol 2004; 31: 635-44
3. Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9
4. McLendon RE, Halperin EC. Is the long-term survival of patients with intracranial glioblastoma multiforme overstated? Cancer 2003; 98: 1745-8
5. Reardon DA, Rich JN, Friedman HS, et al. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24: 1253-65
6. Wolff JE, Trilling T, Molenkamp G, et al. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 1999; 125: 481-6
7. DeAngelis LM. Benefits of adjuvant chemotherapy in high-grade gliomas. Semin Oncol 2003; 30: 15-8
8. Grossman SA. Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomas. Semin Oncol 2003; 30 (6 Suppl. 19): 19-22
9. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-97
10. Glioma Meta-Analysis Trialists (GMT) Group. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev 2002; (3): CD003913
11. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96
12. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
13. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74
14. Egger M, Altman DG, Smith GD. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Publishing Group, 2001
15. McQuay HJ, Moore A. Systematic review series: using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126: 712-20
16. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452-4
17. Cohen J. Statistical power analysis for the behavioral sciences. London: Academic Press, 1969
18. Solero CL, Monfardini S, Brambilla C, et al. Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 1979; 2: 43-8
19. Hildebrand J, Sahmoud T, Mignolet F, et al. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group. Neurology 1994; 44: 1479-83
20. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997; 41: 44-8
21. Fischer SP, Lindermuth J, Hash C, et al. Levamisole in the treatment of glioblastoma multiforme. J Surg Oncol 1985; 28: 214-6
22. Muller H, Brock M, Ernst H. Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 1985; 87: 167-71
23. Garfield J, McDonald H, Punt J, et al. Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 1991; 27: 568-57
24. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996; 53: 43-6
25. Lissoni P, Meregalli S, Fossati V, et al. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori 1993; 79: 198-201
26. Takakura K, Abe H, Tanaka R. Effects of ACNU and radiotherapy on malignant glioma. J Neurosurg 1986; 64: 53-7
27. Sheleg SV, Korotkevich EA, Zhayrid EA, et al. Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002; 60: 53-9
28. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52: 997-1007
29. Cianfriglia F, Pompili A, Riccio A, et al. CCNU-chemotherapy of hemispheric supratentorial glioblastoma multiforme. Cancer 1980; 45: 1289-99
30. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88
31. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509-18
32. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 2005; 23: 2372-7
33. Costanza M, Buechler M, Munzenreider J, et al. Radiation plus adjuvant CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) vs CCNU, hydroxyurea and vincristine in the treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1979; 5: 1589-92
34. Buckner JC, Schomberg PJ, McGinnis WL, et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001; 92: 420-33
35. Grossman SA, O'Neill A, Grunnet M, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 2003; 21: 1485-91
36. Shibata S, Mori K, Moriyama T. Randomized controlled study of the effect of adjuvant immunotherapy with picibanil on 51 malignant gliomas. Surg Neurol 1987; 27: 259-63
37. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; (1): CD002092
38. Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92: 1372-81
39. Bernstein ED, Herbert SM, Hanna NH. Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. Ann Surg Oncol 2006; 13: 291-301
40. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998; 58: 672-84